COMMUNIQUÉS West-GlobeNewswire

Novo Nordisk A/S - share repurchase programme

21/10/2024 - 14:50

Bagsværd, Denmark, 21 October 2024 – On 7 August 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 ( [...]

Stereotaxis Technology to be Featured at Annual Meeting of the Society for Cardiac Robotic Navigation

21/10/2024 - 14:41

ST. LOUIS, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will participate in the [...]

Cerevance Announces Publication of Positive Phase 2 Results of Solengepras for the Treatment of Parkinson’s Disease in eClinicalMedicine

21/10/2024 - 14:38

BOSTON, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Cerevance, a clinical-stage biopharmaceutical company advancing multiple cell type-specific therapies for the treatment of neurodegenerative, psychiatric, and central nervous [...]

Alpha Tau Announces Acceptance Into FDA’s Total Product Life Cycle Advisory Program to Accelerate Market Access to Alpha DaRT® for Patients with Recurrent Glioblastoma Multiforme

21/10/2024 - 14:30

JERUSALEM, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-emitters cancer therapy Alpha DaRT®, announced today that [...]

Revolo Shares New Preclinical Data Showcasing the Potential of Sublingual ‘1104 in Allergic Disease

21/10/2024 - 14:30

Sublingual (SL) formulation of ‘1104 achieved comparable responses to subcutaneous (SQ) and intravenous (IV) injections ‘1104 SC and SL dosing options create opportunities for highly differentiated product profiles in [...]

Bright Minds Biosciences and Firefly Neuroscience to Collaborate After the BREAKTHROUGH Study: A Phase 2 Trial of BMB-101 in Absence Epilepsy and Developmental Epileptic Encephalopathy for Full Analysis of EEG Data

21/10/2024 - 14:30

NEW YORK AND VANCOUVER, British Columbia, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (Bright Minds or the Company) (NASDAQ: DRUG), a biotechnology company focused on developing novel therapies for [...]

KFSHRC Leads the Way in AI-Powered Diagnostics and Minimally Invasive Surgeries

20/10/2024 - 18:21

RIYADH, Saudi Arabia, Oct. 20, 2024 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital & Research Centre (KFSHRC) continues to contribute to advancing healthcare through pioneering advancements in AI-driven [...]

Le KFSHRC, pionnier du traitement du cancer grâce à ses thérapies novatrices et ses résultats exceptionnels

20/10/2024 - 15:18

RIYAD, Arabie saoudite, 20 oct. 2024 (GLOBE NEWSWIRE) -- Le King Faisal Specialist Hospital & Research Centre (« KFSHRC ») révolutionne le traitement du cancer dans la région grâce à des thérapies transformatrices [...]

KFSHRC Pioneers Cancer Treatment with Breakthrough Therapies and Exceptional Outcomes

19/10/2024 - 14:14

RIYADH, Saudi Arabia, Oct. 19, 2024 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital & Research Centre (KFSHRC) is revolutionizing cancer treatment in the region with transformative therapies like CAR-T cell [...]

Nurix Therapeutics Presents Positive Results from the Ongoing Clinical Trial of Its BTK Degrader NX-5948 in Patients with Relapsed/Refractory Waldenstrom’s Macroglobulinemia

19/10/2024 - 14:00

NX-5948 demonstrated robust clinical activity with objective responses observed in 7 of 9 (77.8%) evaluable Waldenstrom’s patients in the ongoing Phase 1a/1b clinical trial Responses are durable and deepen over time [...]

Le KFSHRC impose son leadership en matière de veille dans les soins de santé pour le diagnostic et les soins aux patients

19/10/2024 - 13:16

RIYAD, Arabie Saoudite, 19 oct. 2024 (GLOBE NEWSWIRE) -- Le King Faisal Specialist Hospital & Research Centre (KFSHRC) contribue à l’innovation mondiale en matière de soins de santé, en tirant parti de l’ [...]

NYSE American to Commence Delisting Proceedings with Respect to the Warrants of Calidi Biotherapeutics, Inc. (CLDI WS)

19/10/2024 - 05:00

SAN DIEGO, Oct. 18, 2024 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today [...]

Tevogen CEO Expresses Gratitude for Unprecedented Public Support of Company’s Business Model of Commercial Success Through Patient Accessibility and Reaffirms His Commitment to Share Additional Details in the Coming Days

19/10/2024 - 04:46

WARREN, N.J., Oct. 18, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN ) is a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified [...]

Celularity Inc. Receives Notice from Nasdaq; Confirms Intention to File an Appeal

19/10/2024 - 00:00

FLORHAM PARK, N.J., Oct. 18, 2024 (GLOBE NEWSWIRE) -- Celularity Inc . (Nasdaq: CELU) (the “Company”), a regenerative medicine company developing and commercializing placental-derived technologies, today announced that [...]

Three-year Results for EYLEA HD® (aflibercept) Injection 8 mg Demonstrate Continued Durable Vision Gains and Anatomic Improvements with Extended Dosing Intervals in Patients with Diabetic Macular Edema

18/10/2024 - 23:05

88% of EYLEA HD patients had a last assigned dosing interval of ≥12 weeks at week 156, while sustaining visual and anatomic improvements achieved in the first 96 weeks, in this extension study of the Phase 3 PHOTON [...]

Roche’s Vabysmo improved vision in underrepresented populations with diabetic macular edema (DME) in a first-of-its-kind study

18/10/2024 - 23:00

The ELEVATUM study showed clinically meaningful improvement in vision and reduction in retinal fluid in people with diabetic macular edema (DME) treated with Vabysmo who identify as African American, Black, Hispanic and [...]

Chimerix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

18/10/2024 - 22:31

DURHAM, N.C., Oct. 18, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), today announced that on October 16, 2024, the Compensation Committee of Chimerix’s Board of Directors granted an inducement award to a new employee [...]

DBV Technologies to Participate in Upcoming ACAAI 2024 Congress

18/10/2024 - 22:30

Châtillon, France, October 18, 2024 DBV Technologies to Participate in Upcoming ACAAI 2024 Congress DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical [...]

DBV Technologies participera au prochain congrès de l'ACAAI 2024

18/10/2024 - 22:30

Châtillon, France, le 18 octobre (22 :30 CEST) 2024 DBV Technologies participera au prochain congrès de l'ACAAI 2024 DBV Technologies (Euronext : DBV - ISIN : FR0010417345 - Nasdaq Stock Market : DBVT), société [...]